Treatment of visceral leishmaniasis

  • Shyam Sundar
  • Published 2001 in Medical Microbiology and Immunology

Abstract

Growing antimony resistance in patients with visceral leishmaniasis (VL) over last two decades, especially in Indian subcontinent, renders this cheap and easily available drug useless for a vast majority of patients. Use of the second line drug pentamidine isethionate, a toxic drug with declining efficacy, has largely been abandoned. Thus, in these areas… (More)
DOI: 10.1007/s004300100088

Topics

Cite this paper

@article{Sundar2001TreatmentOV, title={Treatment of visceral leishmaniasis}, author={Shyam Sundar}, journal={Medical Microbiology and Immunology}, year={2001}, volume={190}, pages={89-92} }